BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Trial Details

NCT ID

NCT04271644

Phase

PHASE1 / PHASE2

Sponsor

Chongqing Precision Biotech Co., Ltd

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

• BCMA CAR-T cells

Locations (sample)

• Kunming, Yunnan, China|25.03889,102.71833

Key Eligibility Criteria

• Signed written informed consent;
• Diagnose as relapsed /refractory multiple myeloma or other plasma cell disease, and meet one of the following conditions:
• Failed to standard chemotherapy regimens;
• Relapse after complete remission, high-risk and / or refractory patients ;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.